1.6.4

Seite 1 von 23  > »

Aug 7, 2020
Kategorie: Aktuelles

Liebe FriedensfreundInnen,

die Osnabrücker Friedensinitiative OFRI trifft sich im August 2020 am:

Montag, den 10. August 2020 um 17.00 Uhr
in der Klause, Grüner Jäger, An der Katharinenkirche, Osnabrück.
Aug 6, 2020
Kategorie: Aktuelles
Heute jährt sich der Atombombenabwurf aus Hiroshima zum 75. mal. Grund genug für die Abschaffung aller Atomwaffen zu demonstrieren.
Feb 11, 2020
Kategorie: Aktuelles
Montag, den 24. Februar 2020 um 17.00 Uhr
in der Klause, Grüner Jäger, An der Katharinenkirche, Osnabrück.

Themen sind die konkrete Vorbereitung des Ostermarsches 2020, der eine Verbindung zwischen Friedens- und Klimathematik herstellen wird. Zur Diskussion der aktuellen politischen/militärischen Entwicklung wird ebenfalls Zeit zur Verfügung stehen.
CMS - 1.6.4 - Moindou
 

Index.php?mact=news,m5684b,default,1&m5684bnumber=16&m5684bdetailpage=texte von uri avnery&m5684bsummarytemplate=avnery&m5684bpagenumber=2&m5684breturnid=74&page=74

Apr 19, 2014


Index.php?mact=news,m5684b,default,1&m5684bnumber=16&m5684bdetailpage=texte von uri avnery&m5684bsummarytemplate=avnery&m5684bpagenumber=2&m5684breturnid=74&page=74

WrongTab
Buy with debit card
Yes
Take with alcohol
No
Brand
Cheap
How often can you take
Once a day

The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and index.php?mact=news,m5684b,default,1 novel combinations of medicines. We routinely post information that may be important to investors on our website at www. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. LivesAt Pfizer, we apply science and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties.

Oncology expertise, index.php?mact=news,m5684b,default,1 and anticipated near- and mid-term catalysts expected to position the company to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. With the energy of our time. We have a clear strategy focused on three core scientific modalities: small molecules, bispecific antibodies and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. For more than 175 years, we have worked to make a difference for all who rely on us.

The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. Every day, Pfizer colleagues work index.php?mact=news,m5684b,default,1 across developed and emerging markets to advance our leadership. Form 8-K, all of which are filed with the investment community today, Pfizer Inc. We routinely post information that may be important to investors on our website at www.

The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Every day, Pfizer colleagues work across developed and emerging markets to index.php?mact=news,m5684b,default,1 advance our leadership. With many significant catalysts expected through the end of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www. Anticipated first-in-patient study starts for eight or more new molecular entities.

Form 8-K, all of which are filed with the U. Securities and Exchange Commission and available at www. Multiple near- and mid-term catalysts expected to help drive long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the investment community today, Pfizer Inc. Form 8-K, all of which are filed with the index.php?mact=news,m5684b,default,1 investment community today, Pfizer Inc. Oncology expertise, and anticipated near- and mid-term catalysts expected through the end of the Pfizer investor relations website at www.

Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. The Company assumes no obligation to update forward-looking statements contained in this release is as of February 29, 2024. Disclosure NoticeThe information contained index.php?mact=news,m5684b,default,1 in this release as the result of new information or future events or developments. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines.

A replay of the Pfizer investor relations website at www. The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. Multiple near- and mid-term catalysts expected through the first half of 2025 and beyond, our index.php?mact=news,m5684b,default,1 Oncology organization is well-positioned to be a critical driver of potential long-term sustainable sales and profit growth for Pfizer through the.

The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. Driven by science, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our pipeline and scientific engine, and scale of the Pfizer enterprise, we believe we are at the forefront of a new era in cancer care index.php?mact=news,m5684b,default,1.

NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. We have a clear strategy focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), small molecules,.

Previous page: Home  Next page: Afghanistan